6 patents
Utility
Modified orthopoxvirus vectors
31 Oct 23
The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers.
John C. Bell, Fabrice Le Boeuf, Michael S. Huh, Matthew Y. Tang, Adrian Pelin, Brian Andrew Keller, Caroline J. Breitbach, Michael F. Burgess, Steven H. Bernstein
Filed: 4 Jan 19
Utility
Modified Orthopoxvirus Vectors
1 Dec 22
The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers.
John C. BELL, Michael S. HUH, Matthew Y. TANG, Adrian PELIN, Caroline J. BREITBACH, Michael F. BURGESS, Steven H. BERNSTEIN
Filed: 20 Dec 19
Utility
Methods for Inducing an Immune Response Against Neoantigens
29 Sep 22
Provided herein is a method for inducing an immune response to at least one neoantigen, the method comprising administering to a subject a priming composition comprising a peptide antigen conjugate and at least a first boost.
David STOJDL, Geoffrey Martin LYNN, Andrew Scott ISHIZUKA
Filed: 26 Aug 20
Utility
Methods for Inducing an Immune Response Against Neoantigens
26 May 22
In one aspect, provided herein is a heterologous boost method for inducing an immune response to at least one neoantigen, the method comprising administering to a subject a first boost and subsequently administering to the subject a second boost, wherein the first boost comprises a first oncolytic virus comprising a genome that expresses, in the subject, a first peptide, or the first boost comprises a first oncolytic virus and a second peptide, wherein the second boost comprises a second oncolytic virus comprising a genome that expresses, in the subject, a third peptide, or the second boost comprises a second oncolytic virus and a fourth peptide, wherein the first peptide, the second peptide, the third peptide, and the fourth peptide are each capable of inducing an immune response to at least one neoantigen, and wherein the second oncolytic virus is immunologically distinct from the first oncolytic virus.
David Stojdl, Justyna KMIECIK, Michael F. BURGESS
Filed: 19 Mar 20
Utility
Modified Orthopoxvirus Vectors
24 Feb 22
The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers.
John C. BELL, Michael S. HUH, Matthew Y. TANG, Adrian PELIN, Caroline J. BREITBACH, Michael F. BURGESS, Steven H. BERNSTEIN
Filed: 20 Dec 19
Utility
Modified Orthopoxvirus Vectors
16 Dec 20
The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers.
John C. BELL, Fabrice LE BOEUF, Michael S. HUH, Matthew Y. TANG, Adrian PELIN, Brian Andrew KELLER, Caroline J. BREITBACH, Michael F. BURGESS, Steven H. BERNSTEIN
Filed: 3 Jan 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first